Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.6652W HIGH $4.33
Volume
6.07 M
Value Traded
4.15 M
Short % Float
21.63%
+8.4%Week
+2.53%1 Month
-12.88%3 Month
-3.4%6 Month
-92.05%5 Year
-84.67%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
436.17 M
EPS (TTM)
-0.48
P/E Ratio
-
Ent. Value
280.26 M
Total Shares
153.58 M
Float Shares
138.53 M
Insiders
9.80%
Institutions
69.38%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
EDIT Catalyst Timeline
Dated clinical, regulatory and corporate events for Editas Medicine, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Editas Medicine, Inc.
624Total events
15Upcoming
90Tier-1 (high impact)
2016 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Trial Authorization (CTA / IND)EDIT-401Ex-US Regulatory
Clinical Trial Notification (CTN) process completed with Australia's TGA for Strive trial of EDIT-401
Heterozygous Familial Hypercholesterolemia (HeFH)source ↗
▲Ethics Committee ApprovalEDIT-401Trial
HREC approval for Phase 1/2 Strive trial of EDIT-401 in Australia
Heterozygous Familial Hypercholesterolemia (HeFH)source ↗
●IND SubmissionEDIT-401IND
CTN submission for EDIT-401 in Australia expected this month
Heterozygous Familial Hypercholesterolemia (HeFH)source ↗
●IND SubmissionEDIT-401IND
Plan to submit CTN in Australia to TGA by mid-2026
Heterozygous Familial Hypercholesterolemiasource ↗
▼Equity OfferingCorporate
Pricing of underwritten public offering of common stock and warrants
▲FDA Feedback ReceivedEDIT-401FDA Meeting
Positive pre-IND feedback from FDA on nonclinical package, CMC plans, and study design
Heterozygous Familial Hypercholesterolemiasource ↗
◆Oral PresentationEDIT-401Presentation
Oral presentation at EAS Congress 2026: In vivo CRISPR gene editing upregulates LDLR and reduces LDL-C in non-human primates
hyperlipidemiasource ↗
◆Oral PresentationEDIT-401Presentation
Oral presentation at ASGCT 2026: Preclinical Development of EDIT-401
hyperlipidemiasource ↗
◆Poster PresentationEDIT-401Presentation
Poster presentation at ASGCT 2026: PK/PD of EDIT-401 in mice
hyperlipidemiasource ↗
▲Preclinical PoCEDIT-401Preclinical
Preclinical data: ≥90% mean LDL-C reduction in NHPs with single dose
hyperlipidemiasource ↗
◆Poster PresentationEDIT-401Presentation
Poster presentation at ASGCT 2026: In vivo CRISPR-based disruption of gene repressor element
hyperlipidemiasource ↗
◆Oral PresentationEDIT-401Presentation
Oral presentation at TIDES USA 2026: Transformative LDL Cholesterol Lowering
hyperlipidemiasource ↗
◆Oral PresentationEDIT-401Presentation
Preclinical data at ASGCT 29th Annual Meeting
hyperlipidemiasource ↗
▲Preclinical PoCEDIT-401Preclinical
EDIT-401 demonstrated >90% mean LDL-C reduction in preclinical studies
hyperlipidemiasource ↗
▼Equity OfferingCorporate
Completed public offering of common stock and warrants with gross proceeds of $125.0 million
▲IP Litigation RulingIP / Competition
PTAB reaffirms Broad Institute as first to invent CRISPR/Cas9 in eukaryotic cells
▼IP Litigation RulingIP / Competition
USPTO reaffirmed PTAB decision favoring Broad Institute in CRISPR/Cas9 interference
●Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference Fireside Chat
◆Oral PresentationPresentation
Management to participate in upcoming investor conferences in March
▲First Patient DosedEDIT-401Trial
Initiation of first-in-human clinical trial of EDIT-401 later in 2026
Heterozygous Familial Hypercholesterolemiasource ↗
▲Preclinical PoCEDIT-401Preclinical
Preclinical data presented at EAS, ASGCT, and TIDES USA 2026 showing ~90% mean reduction in atherogenic lipoproteins in NHPs
Hyperlipidemiasource ↗
◆Pipeline PrioritizationCorporate
Establish and disclose one additional target cell type/tissue beyond HSCs and liver
Additional cell type/tissue beyond HSCs and liversource ↗
▲Preclinical PoCEDIT-401Preclinical
In vivo preclinical proof-of-concept data presented at AHA and ESGCT showing >90% LDL-C reduction in non-human primates
hypercholesterolemiasource ↗
◆Poster PresentationEDIT-401Presentation
Moderated digital poster presentation at AHA Scientific Sessions 2025
▲Oral PresentationEDIT-401Presentation
In vivo proof-of-concept data for EDIT-401 presented at ESGCT 2025
high LDL cholesterolsource ↗
◆Oral PresentationEDIT-401Presentation
EDIT-401 oral presentation at ESGCT 32nd Annual Congress
◆Development Candidate NominationPreclinical
Webinar to announce lead in vivo development candidate
▲Development Candidate NominationEDIT-401Preclinical
EDIT-401 nominated as lead in vivo development candidate
hyperlipidemiasource ↗
▲Preclinical PoCEDIT-401Preclinical
EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates
hyperlipidemiasource ↗
●Pipeline PrioritizationCorporate
Company to focus resources on EDIT-401; continues HSC program optimization
Past FDA Catalysts and PDUFA Decisions
How EDIT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | Lead Program | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D29 / 100
Pipeline Score
$14M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 71%
Micro Cap(rank 467 of 658)
Percentile Rank
Editas Medicine, Inc. faces pipeline headwinds (29/100), with $109M risk-adjusted pipeline value, led by EDIT-301 in Sickle Cell Disease (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EDIT-301 Gene therapyNCT04853576 | Sickle Cell Disease | Phase 1 | ACTIVE NOT_RECRUITING | 45 | Aug 1, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every EDIT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| EDIT-401 | Heterozygous Familial Hypercholesterolemia | Phase 1/2 | 2026-08-05 | over 90% reduction in atherogenic lipoproteins; LDL-C mean reduction of ≥90% with a single dose of EDIT-401 in NHPs was durable through ~6 months; No adverse clinical observations were observed in NHPs at a single dose of 1.5mg/kgRead More | Editas Medicine Announces Second Quarter 2026 Results and Business UpdatesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Parison AmyOfficer (SVP, Chief Financial Officer) | Sell | -453 13,839 held | $3.04 | 09/03/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EDIT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 0.9 % | 36.00 M | 11.11 M |
EDIT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EDIT ranks across every disease it competes in
Competitive Position is a premium feature
See how EDIT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEDIT News
EDIT▲ +4.6%today
Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
Editas Medicine has received approval to start the Phase 1/2 Strive clinical trial for EDIT-401, targeting patients with Heterozygous Familial Hypercholesterolemia in Australia. The trial aims to assess the safety, tolerability, and efficacy of EDIT-401, a gene editing therapy designed to lower LDL-C levels. Initial safety data is anticipated in the first quarter of 2027, with further presentations planned at the AHA Scientific Sessions 2026.
Read more →EDIT▼ -8.6%on this news
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
Editas Medicine has announced the appointment of Dr. Daniel Ory as the new Chief Medical Officer. As part of his inducement package, Dr. Ory will receive stock options to purchase up to 950,000 shares at a price of $3.03 per share. The options will vest over four years, contingent on his continued service with the company.
Read more →EDIT▼ -6.2%on this news· ran to -16% by day 3
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Editas Medicine has appointed Dan Ory, M.D., as Chief Medical Officer to lead clinical development. With over 25 years of experience in biotechnology and cardiovascular medicine, Dr. Ory will oversee the advancement of EDIT-401, a gene editing candidate for hyperlipidemia. His expertise is expected to enhance the company's clinical strategy and pipeline.
Read more →EDITEditas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine will participate in two upcoming investor conferences in September 2026. The events include the Wells Fargo Healthcare Conference on September 8 and the Cantor Global Healthcare Conference on September 10. Management will engage in fireside chats at both conferences, emphasizing the company's commitment to investor relations and transparency.
Read more →EDIT▲ +5.5%on this news
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
Editas Medicine reported positive preclinical results for EDIT-401, which demonstrated over 90% reduction in atherogenic lipoproteins in non-human primates. The company is on track to submit a Clinical Trial Notification in Australia and expects to initiate a Phase 1/2 trial for patients with Heterozygous Familial Hypercholesterolemia. Recent financing has bolstered the company's capital position, ensuring continued development of EDIT-401.
Read more →EDITEditas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
Editas Medicine announced the appointment of Dr. Patrick T. Ellinor to its Board of Directors, effective August 6, 2026. Dr. Ellinor, a leader in cardiovascular research, will replace Elliott Levy, M.D., who is stepping down. His expertise is expected to enhance Editas's strategic direction as the company advances its gene editing therapies.
Read more →EDITEditas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
Editas Medicine has announced an updated presentation time for its participation in the 2026 Jefferies Global Healthcare Conference. The presentation is scheduled for June 4, 2026, at 2:00 p.m. ET. The company aims to showcase its advancements in gene editing and its commitment to developing innovative therapies for serious diseases.
Read more →EDIT▲ +11.6%on this news· ran to +29% by day 1shared move
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
Editas Medicine presented promising preclinical data for EDIT-401 at the European Atherosclerosis Society Congress. The treatment achieved significant reductions in LDL-C, Lp(a), and ApoB in non-human primates, indicating its potential as a leading therapy for hyperlipidemia. The company plans to submit a Clinical Trial Notification by mid-2026 and aims for early human proof-of-concept data by the end of 2026.
Read more →EDIT▲ +11.6%on this news· ran to +29% by day 1shared move
Editas Medicine Announces Proposed Public Offering
Editas Medicine has announced a proposed public offering of its common stock and accompanying warrants. The offering is managed by Cantor and Wells Fargo Securities and is subject to market conditions. The company aims to leverage its expertise in gene editing to develop innovative treatments for serious diseases. However, the completion and terms of the offering remain uncertain.
Read more →EDIT▲ +11.6%on this news· ran to +29% by day 1shared move
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
Editas Medicine has announced a public offering of 55,555,556 shares at a price of $2.25 each, aiming to raise approximately $125 million. If all warrants are exercised, total proceeds could reach $319.4 million. The offering is expected to close on May 27, 2026, pending customary conditions. This move is part of Editas's strategy to fund its gene editing initiatives.
Read more →EDITEditas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
Editas Medicine has presented new preclinical data for EDIT-401, indicating its potential as a one-time treatment for hyperlipidemia at the ASGCT 2026 Annual Meeting. The data showed a significant reduction of mean LDL-C by over 90% in non-human primates with a durable response lasting around 6 months. Additionally, the treatment demonstrated a promising safety profile without adverse effects at relevant doses. The findings also explore the potential of Editas' gene upregulation strategy for broader therapeutic applications.
Read more →EDITEditas Medicine Announces First Quarter 2026 Results and Business Updates
Editas Medicine (EDIT) announced its financial results for Q1 2026, highlighting advancements in EDIT-401, a gene editing therapy targeting hyperlipidemia. The company aims to achieve early human proof-of-concept data by the end of 2026. Despite recent positive preclinical results, including significant LDL-C reduction, Editas faces challenges, including reaffirmed patent decisions that may hinder its CRISPR technology. Overall, while the outlook for EDIT-401 remains optimistic, financial losses and revenue declines present areas of concern.
Read more →EDIT▲ +5.9%on this news
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
Editas Medicine announced that five abstracts have been accepted for presentation at upcoming scientific conferences, showcasing new preclinical data on EDIT-401. This gene editing therapy aims to lower LDL cholesterol levels and may offer a transformative treatment for hyperlipidemia. Presentations will occur at the ASGCT Annual Meeting, TIDES USA Conference, and EAS Congress.
Read more →EDITEditas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
Editas Medicine announced that the U.S. Patent and Trademark Office reaffirmed a previous decision favoring the Broad Institute in a patent interference case regarding CRISPR/Cas9 technology. This decision reinforces Broad's inventorship priority for gene editing in human cells. Editas holds exclusive licenses for these patents, supporting its development of innovative gene editing therapies.
Read more →EDIT▲ +16%on this news· ran to +32% by day 1
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
Editas Medicine reported its financial results for Q4 and full year 2025, highlighting significant progress with its lead candidate, EDIT-401, which showed over 90% LDL-C reduction in preclinical studies. The company is preparing for an IND/CTA submission by mid-2026 and aims to initiate a first-in-human trial for HeFH patients. Despite a strong cash position, the company reported increased net losses for the year.
Read more →EDITGenflow Biosciences PLC Announces Directorate Change
Genflow Biosciences has appointed Gad Berdugo as the new Independent Non-Executive Chairman. This strategic move aims to enhance the company's focus on gene therapies for age-related diseases. Berdugo brings over 30 years of experience in biotechnology and corporate development, which is expected to accelerate Genflow's R&D efforts and global presence.
Read more →EDITEditas Medicine Announces Third Quarter 2025 Results and Business Updates
Editas Medicine reported strong third quarter results for 2025, highlighting promising preclinical data for its lead candidate, EDIT-401, which demonstrated over 90% reduction in LDL cholesterol in non-human primates. The company is on track to submit an IND/CTA for EDIT-401 by mid-2026 and aims to achieve initial human proof-of-concept data by the end of 2026. Additionally, Editas has extended its cash runway into the third quarter of 2027, ensuring continued development of its therapies.
Read more →EDITEditas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
Editas Medicine announced a moderated digital poster presentation of EDIT-401 at the American Heart Association (AHA) Scientific Sessions 2025. The event will take place from November 7-10 in New Orleans, Louisiana. The accepted abstract is available on the AHA website, and the poster will be accessible on Editas' website during and after the event.
Read more →About Editas Medicine, Inc.
Headquarters11 HURLEY ST., CAMBRIDGE, MA, 02141
BIOPHARMAWATCH ELITE PLUS
Trade the next EDIT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime